Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel
October 03 2017 - 8:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced
that it has further strengthened its leadership team with the
appointment of Sumita Ray as Senior Vice President, General Counsel
and Chief Compliance Officer.
With more than 17 years of pharmaceutical and biotechnology
experience, Ms. Ray brings a breadth of knowledge in FDA regulatory
law, global health care law and compliance, brand support, product
launches, collaborations and alliances. Prior to joining
Calithera, she served as Chief Compliance Officer and Associate
General Counsel, Head of Healthcare and Regulatory Law at
Pharmacyclics, where she supported the company through the global
approval and launch of Imbruvica in multiple indications.
Previously, Ms. Ray served as Head of BioNeurology & Regulatory
Law Group at Elan Pharmaceuticals, Corporate Counsel, Commercial
Law Group at Genentech and Corporate Counsel at AstraZeneca.
Ms. Ray started her career as a pharmaceutical and products
liability litigator at Montgomery, McCracken, Walker and Rhoads
LLP.
Ms. Ray holds a J.D. from Temple University School of Law and a
B.S. in Microbiology from the University of Arizona.
About Calithera Calithera Biosciences, Inc. is
a clinical-stage pharmaceutical company focused on discovering and
developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of
cancer. Calithera’s lead product candidate, CB-839, is a
potent, selective, reversible and orally bioavailable inhibitor of
glutaminase. CB-839 takes advantage of the pronounced dependency
many cancers have on the nutrient glutamine for growth and
survival. It is currently being evaluated in Phase 2 clinical
trials in combination with standard of care agents. CB-1158
is a first-in-class immuno-oncology metabolic checkpoint inhibitor
targeting arginase, a critical immunosuppressive enzyme responsible
for T-cell suppression by myeloid-derived suppressor cells.
Arginase depletes arginine, a nutrient that is critical for the
activation, growth and survival of the body’s cancer-fighting
immune cells, known as cytotoxic T-cells. CB-1158 is being
developed in collaboration with Incyte Corporation and is currently
in a Phase 1 clinical trial. Calithera is headquartered in
South San Francisco, California. For more information about
Calithera, please visit www.calithera.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
"may," "will," "expect," "anticipate," "estimate," "intend,"
"poised" and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking
statements. These statements include those related to the
timing of Calithera’s clinical trials, the clinical and commercial
potential of its product candidates, Calithera’s ability to fund
its clinical programs, and Calithera’s receipt of clinical data
from its clinical trials. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking
statements. The potential product candidates that Calithera
develops may not progress through clinical development or receive
required regulatory approvals within expected timelines or at
all. In addition, clinical trials may not confirm any safety,
potency or other product characteristics described or assumed in
this press release. Such product candidates may not be beneficial
to patients or successfully commercialized. The failure to
meet expectations with respect to any of the foregoing matters may
have a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
Contact:Jennifer
McNealeyir@Calithera.com650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024